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What is the role of single-agent interleukin-2 (IL-2)
in the treatment of adults with metastatic melanoma?
If there is a role for single-agent IL-2, what pa-
tient population can appropriately be considered for
treatment?
If there is a role for single-agent IL-2, what dose
and schedule are appropriate?
What are the toxicities associated with IL-2?
Perspectives
Many agents have been investigated for antitumour
activity in melanoma, but few have shown promis-
ing response rates. Early detection, appropriate sur-
gery, and adjuvant therapy have all improved
outcomes, but approximately one third of patients
with early-stage disease will nevertheless develop
metastases. Single-agent IL-2 has attracted much at-
tention over the past several years. A number of ran-
domized trials and many phase II trials investigating
single-agent IL-2 suggest that this systemic treatment
produces durable responses in melanoma patients.
Given the dismal survival of patients with meta-
static melanoma and the limited availability of effec-
tive treatments, the Melanoma Disease Site Group
(DSG) of Cancer Care Ontario’s Program in Evidence-
Based Care (PEBC) felt that the durable responses seen
with IL-2 treatment warranted closer examination.
Outcomes
Primary outcomes of interest included objective re-
sponse rate, complete response rate, duration of re-
sponse, toxicity, and quality of life. Secondary
outcomes of interest included progression-free sur-
vival and overall survival.
Methodology
A systematic review was developed, and clinical rec-
ommendations relevant to patients in Ontario were
drafted. The practice guideline report was reviewed
and approved by the Melanoma DSG, which comprises
medical oncologists, surgeons, and dermatologists.
External review by Ontario practitioners was obtained
through a mailed survey, the results of which were
incorporated into the practice guideline. Final review
and approval of the practice guideline was obtained
from the PEBC’s Report Approval Panel.
Results
The present practice guideline reflects the integra-
tion of the draft recommendations based on a sys-
tematic review of the available evidence with the
feedback obtained from external review by practitio-
ners and the Report Approval Panel.
Practice Guideline
No studies have compared IL-2 to the current stan-
dard of care—dacarbazine (DTIC)—or to placebo in
the treatment of metastatic melanoma. After review-
ing and weighing the evidence that does exist, the
opinion of the Melanoma DSG is that high-dose IL-2 is
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a reasonable treatment option for a select group of
patients with metastatic melanoma:
• Patients should have a good performance status
(Eastern Cooperative Oncology Group 0–1) and
a normal lactate dehydrogenase level.
• Patients should have fewer than three organs in-
volved or have cutaneous and/or subcutaneous
metastases only, and no evidence of central ner-
vous system metastases should be present.
In this select group of patients, IL-2 treatment can
produce durable complete remissions.
High-dose IL-2 is recommended to be given at
600,000 IU/kg per dose, delivered intravenously over
15 minutes, every 8 hours, for a maximum of
14 doses. High-dose IL-2 delivery is recommended
to be done in a tertiary-care facility by staff trained
in the provision of this treatment and with appropri-
ate monitoring. To facilitate treatment and to develop
expertise in this therapeutic modality, the DSG recom-
mends that high-dose IL-2 programs be established
in one or two centres in Ontario.
Qualifying Statements
High-dose IL-2 has response rates that are similar to
those seen with standard chemotherapy. However,
unlike chemotherapy, IL-2 demonstrates low but du-
rable complete response rates that may lead to years
of benefit for patients with metastatic melanoma.
Based on the available data assessing prognostic
factors and patient selection, patients with non-vis-
ceral metastases and fewer metastatic sites have a
much higher response rate. In these select patients,
high dose IL-2 may be considered for first-line therapy.
The lack of large randomized trials comparing
IL-2 to DTIC or other chemotherapy means that rec-
ommendations for this guideline are based largely on
phase II data and limited phase III data. Further ran-
domized data will not soon become available, because
no randomized trials are currently ongoing or planned.
Interleukin-2 is currently widely used in the United
States, and it is an approved therapy in both Canada
and the United States.
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1. QUESTION
What is the role of single-agent interleukin-2 (IL-2)
in the treatment of adults with metastatic melanoma?
Primary outcomes of interest included objective re-
sponse rate, complete response (CR) rate, duration of
response, toxicity, and quality of life (QOL). Second-
ary outcomes of interest included progression-free
survival and overall survival.
If there is a role for single-agent IL-2, what pa-
tient population can appropriately be considered for
treatment?
If there is a role for single-agent IL-2, what dose
and schedule are appropriate?
What are the toxicities associated with IL-2?
2. CHOICE OF TOPIC AND RATIONALE
Like just a few other malignancies, malignant mela-
noma continues to increase in both incidence and
mortality. In 2005 in Canada, approximately 4400
new melanoma cases were expected to be diagnosed,
and 880 patients to die from the disease 1. Part of this
increase can be attributed to more frequent diagnosis
of earlier-stage lesions, but diagnosis cannot be the
sole contributing factor, because mortality rates for
melanoma are also increasing. The increasing mor-
tality suggests that new methods are required to treat
the disease, either to prevent recurrence or when sur-
gery is no longer feasible.
Despite low response rates, rare durable re-
sponses, and lack of a survival benefit, dacarbazine
(DTIC) is currently considered to be the standard treat-
ment for metastatic melanoma 2–4.
Given the dismal survival rate for patients with
metastatic melanoma and the limited availability of
effective treatments, the Melanoma DSG felt that IL-2
treatment warranted closer examination.
3. METHODS
3.1 Guideline Development
The present practice guideline report was developed
by the Melanoma DSG of Cancer Care Ontario’s Pro-
gram in Evidence-Based Care (PEBC), using the meth-
ods of the practice guidelines development cycle 5. It
is a convenient and up-to-date source of the best avail-
able evidence on IL-2 treatment for patients with
metastatic melanoma, developed through systematic
review, evidence synthesis, and input from practitio-
ners in Ontario. The systematic review that forms the
basis of this report (and that is currently under con-
sideration for publication elsewhere) was used by the
Melanoma DSG to formulate draft recommendations
promoting evidence-based practice in Ontario.
External review for the practice guideline report
was obtained through a mailed survey of Ontario prac-
titioners. The survey consisted of items that addressed
the quality of the draft practice guideline report and
asked whether the recommendations should serve as
a practice guideline. The efficacy of the external re-
view process has been described elsewhere 6. Final
approval of the original practice guideline report was
obtained from the PEBC’s Report Approval Panel. All
members of the Melanoma DSG disclosed informa-
tion on potential conflicts of interest. No conflicts
were declared.PRACTICE GUIDELINE SERIES
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3.2 Literature Search Strategy
The MEDLINE, EMBASE, and Cochrane Library databases
(1985 to 2006) were systematically searched for eli-
gible randomized phase III and II trials. Abstracts pub-
lished in the proceedings of the 1997–2005 annual
meetings of the American Society of Clinical Oncol-
ogy were also systematically searched for evidence
relevant to the present practice guideline report.
3.3 Results
One systematic review 7, five randomized trials 8–12
that compared single-agent IL-2 with IL-2 combina-
tion therapy, and twelve single-arm phase II trials 13–25
(one of which was reported in two separate publica-
tions 15,16) were eligible for inclusion in this system-
atic review of the evidence. In addition, the literature
search identified a QOL report 24 for patients included
in one of the randomized trials.
None of the randomized controlled trials (RCTs)
compared single-agent IL-2 to standard therapy or to
placebo. In addition, the RCTs included varying regi-
mens and doses of IL-2 and combined IL-2 with various
agents (lymphokine-activated killer cells, interferon,
and histamine dihydrochloride). Because of this het-
erogeneity in the RCTs, the Melanoma DSG decided
against performing a meta-analysis of the results.
Data from three RCTs 8–10 demonstrated that single-
agent IL-2, when given in high doses, can elicit an ob-
jective response rate of 5%–27%, with a CR in 0%–4%
of patients. In addition, patients who achieved a CR in
the five randomized trials also demonstrated consis-
tent long-term response rates that ranged from 6 months
to 66+ months (median: 27 months). Similarly, the non-
comparative phase II trials of high-dose single-agent
IL-2 13–15 consistently reported objective response rates
of 10%–33% with a CR rate ranging from 0% to 15%.
Complete responders in these trials also demonstrated
impressive long-term responses that ranged from
1.5 months to 148 months (median: 70 months).
The gathered data show that carefully selected pa-
tients have the highest chance of response. Patients with
a good performance status [Eastern Cooperative On-
cology Group (ECOG) 0–1], a normal lactate dehydro-
genase (LDH) level, and fewer than three organs involved
or cutaneous and/or subcutaneous metastases only have
the highest probability of responding and achieving a
durable CR. This carefully selected group of patients
should be considered for treatment with high-dose IL-2.
4. DSG CONSENSUS PROCESS
The draft guideline was circulated for review and dis-
cussion by the Melanoma DSG on June 21, 2005. Most
of the members conceded that, given the available data,
it would be optimal to use IL-2 as first-line therapy in
a select group of patients when disease burden is at its
lowest. However, it should be noted that one member
of the Melanoma DSG was not comfortable with the
recommendations set out in this document, stating that
IL-2 “is and remains an investigational drug” and thus
should not be used as standard therapy.
5. PRACTITIONER FEEDBACK
Recommendations in the form of a draft practice guide-
line report and systematic review were prepared by the
Melanoma DSG and circulated to Ontario practitioners.
5.1 Methods
Feedback was obtained through a mailed survey of
176 practitioners in Ontario (medical oncologists,
radiation oncologists, and surgeons). The survey con-
sisted of items evaluating the methods, results, and
interpretive summary used to inform the recommen-
dations and whether the recommendations should be
approved as a practice guideline. Written comments
were invited. The survey was mailed July 8, 2005.
Follow-up reminders were sent at 2 weeks (post card)
and 4 weeks (complete package mailed again). The
Melanoma DSG reviewed the results of the survey.
5.2 Results
Of the 176 surveys mailed, 65 responses were received
(37% response rate). Responses included returned com-
pleted surveys plus telephone, fax, and e-mail re-
sponses. Of the practitioners who responded, 29 (45%)
indicated that the report was relevant to their clinical
practice, and they completed the survey. Most of the
practitioners surveyed (93%) indicated that a practice
guideline on this topic was needed. All the respon-
dents agreed that the draft recommendations in the
report are clear, and 90% agreed with the recommen-
dations as stated. Most respondents (82%) agreed that
the report should be approved as a practice guideline.
5.3 Summary of Written Comments
Twenty-two respondents (76%) provided written
comments. These were the main points contained in
the written comments:
• Two practitioners felt that the evidence was in-
sufficient to recommend the use of IL-2 over other,
less toxic drugs. One of these two practitioners
stated that the evidence of benefit is overstated
and noted that, in several studies, the toxic death
rate approximates CR rates. This practitioner
pointed out that the guideline does not indicate
“how to select eligible patients or what evidence
supports selection (i.e., no prospective studies
showing selected patients do better).” A third prac-
titioner also agreed that only a limited group would
benefit and that it would be difficult to determine
those fit enough to withstand the treatment.PETRELLA et al.
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• Six respondents provided favourable comments and
supported the guideline recommendations. Two of
those six practitioners felt that administering IL-2
in Ontario is a more economically feasible option
than is sending patients to the United States. One
respondent felt that treating complete responders
would be practical; however, the challenge in es-
tablishing wait lists for those patients and centres
in which to treat them, together with other associ-
ated financial costs, would limit the application of
the guidelines. It was also suggested that issues such
as the cost of medicine, hospital visits, and treat-
ment of complications should be addressed.
• Nine practitioners stated that they do not treat mela-
noma or that the guideline does not apply to them.
• Six practitioners provided suggestions for future
topics.
5.4 Modifications/Actions
The Melanoma DSG discussed the comments resulting
from practitioner feedback and responded as follows:
• The DSG acknowledged that high-quality evidence
suggesting a clear survival benefit for IL-2 therapy
is currently lacking. However, given the dismal
survival of patients with metastatic melanoma and
the fact that no other therapy offers the possibil-
ity of a durable complete remission, the DSG be-
lieves that recommending the use of high-dose
IL-2 to a select group of patients is reasonable.
The specific patient eligibility for this treatment
is defined in the document.
• The DSG also agreed that high-dose IL-2 therapy pre-
sents considerable grades 3 and 4 toxicity. However;
these adverse effects have become increasingly
manageable, and they resolve upon termination of
treatment. Delivery of the treatment by adequately
trained professionals in a designated tertiary care
facility and following the National Cancer Institute’s
guidelines for safe administration will ensure safety
and proper patient monitoring.
• The Melanoma DSG agreed that administering IL-2
therapy in Ontario, rather than referring patients
to the United States for this treatment, is a more
economically feasible option. Creating high-dose
IL-2 programs in one or two centres in Ontario
will not only facilitate patient treatment, but will
also develop expertise in this therapeutic modal-
ity. The DSG recognized the importance of the
financial concerns raised by some of the practi-
tioner respondents; however, the DSG’s main ob-
ligation is to establish clinical effect and
determine best evidence-based practice. Thus, as-
sessing issues of cost and economic benefit is
outside of the purview of this document.
The DSG therefore decided to make no changes to
the draft guideline.
6. REPORT APPROVAL PANEL
The final evidence-based report was reviewed and
approved by the PEBC’s Report Approval Panel in May
2006. The Panel consists of two members, including
an oncologist with expertise in clinical and method-
ology issues.
6.1 Results
Key issues raised by the PEBC Report Approval Panel
included these:
• The RCTs address all of the relevant outcomes, al-
though the data from the phase II trials are more
favourable. Inclusion of the phase II data could be
viewed as biased; clearer justification for the inclu-
sion of the phase II data should therefore be provided.
• Further discussion of the trade-offs of treatment
would be useful. The treatment may offer the best
palliation option; however, it can lead to a miser-
able death with adverse effects for a slim chance
of survival with unknown QOL because no appro-
priate comparisons are available.
• It appears that access to this treatment is a topical
subject, although the relevant background becomes
apparent only in the section on practitioner feed-
back. If access to therapy was a factor that contrib-
uted to the DSG’s selection of this topic, it would be
appropriate to state this fact in the introduction.
• The recommendations are based principally on
studies that provide a lower level of evidence and
that assess an outcome that does not usually drive
policy decisions. The DSG has done a relatively good
job of explaining how it concluded that a recom-
mendation to support availability of this therapy
was appropriate. However, given the relatively un-
usual nature of recommending a therapy based on
such data, and given the toxicity of the agent (in
that special sites of provincial expertise may have
to be developed), the DSG needs to go further in
addressing how the potential benefits of this therapy
“outweigh” the limitations of the data. Specifically:
• Context regarding the importance of response
as an outcome measure would be helpful.
• An indication of whether the prolonged peri-
ods of disease control seen in patients with a
more complete response is unique or whether
responses of this kind are seen in patients who
respond to other therapies would be helpful.
There is a further risk of criticism that the DSG
has compared overall responses to IL-2 with
the historical results associated with other
therapies, but is providing only the data for
durable responses with IL-2.
• The DSG also risks criticism for considering IL-2
as first-line therapy, given that this consideration
appears to be based principally on analyses of
prognostic factors. The difficulty is that patientsPRACTICE GUIDELINE SERIES
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with earlier-stage disease will always do better
than those with more advanced disease, regard-
less of the therapy provided. More background
is required to support this supposition.
• The DSG also should consider providing broader
context for the Agarwala study. This RCT was the
largest of those reported, and it described differ-
ences in median time to disease progression (likely
a more “policy–determining” outcome than re-
sponse) and median quality-adjusted survival. Al-
though the potential limitations of these data can
be appreciated, an explanation of the reasons for
not using the results of this trial to form recom-
mendations when trials that have more severe limi-
tations have been used would be helpful.
6.2 Modifications/Actions
The Melanoma DSG discussed the comments result-
ing from the PEBC Report Approval Panel and re-
sponded with these comments and modifications:
• The DSG felt that the inclusion of phase II data was
necessary because of the limited availability of
phase III data. To further justify the inclusion of
phase II data, a Qualifying Statement was added
to the document.
• The DSG points out that IL-2 is not a palliative treat-
ment. The response rates offered by IL-2 are simi-
lar to those offered by the current standard of care,
DTIC; adverse events are manageable and revers-
ible; and death attributable to treatment is no
longer common.
• Access to therapy was not a contributing factor in
the DSG’s selection of this topic. The purpose of
the present document is to establish clinical ef-
fect and to determine best evidence-based prac-
tice. However, the DSG acknowledges that access
to treatment is addressed in the document.
• The discussion section of the systematic review
was expanded to further address the benefits of
IL-2 therapy, and Qualifying Statements were
added to explain the DSG’s decision to recommend
IL-2 as first line therapy.
• The DSG decided not to use the results of the
Agarwala trial to form its recommendations be-
cause that trial randomized its patients to treat-
ment with low-dose IL-2. Low-dose IL-2 has
consistently lower overall response rates (2%–5%)
than does high-dose IL-2, and hence low-dose treat-
ment was not part of the recommendation.
7. PRACTICE GUIDELINE
The present practice guideline reflects the integra-
tion of the draft recommendations with feedback ob-
tained from the external review process. The guideline
has been approved by the Melanoma DSG and the
PEBC’s Report Approval Panel.
7.1 Recommendations
No studies have compared IL-2 to the current stan-
dard of care—dacarbazine (DTIC)—or to placebo in
the treatment of metastatic melanoma. After review-
ing and weighing the evidence that does exist, the
opinion of the Melanoma DSG is that high-dose IL-2 is
a reasonable treatment option for a select group of
patients with metastatic melanoma:
• Patients should have a good performance status
(ECOG 0–1), and a normal LDH level.
• Patients should have fewer than three organs in-
volved or have cutaneous and/or subcutaneous
metastases only, and they should have no evi-
dence of central nervous system metastases.
In this select group of patients, IL-2 treatment can
produce durable complete remissions.
High-dose IL-2 is recommended to be given at
600,000 IU/kg per dose, delivered intravenously over
15 minutes, every 8 hours, for a maximum of
14 doses. High-dose IL-2 delivery is recommended
to be done in a tertiary-care facility by staff trained
in the provision of this treatment and with appropri-
ate monitoring. To facilitate treatment and develop
expertise in this therapeutic modality, the DSG recom-
mends that high-dose IL-2 programs be established
in one or two centres in Ontario.
7.1 Qualifying Statements
High dose IL-2 has response rates that are similar to
those seen with standard chemotherapy. However,
unlike chemotherapy, IL-2 demonstrates low but du-
rable complete response rates that may lead to years
of benefit for patients with metastatic melanoma.
Based on the available data assessing prognostic
factors and patient selection, patients with non-vis-
ceral metastases and fewer metastatic sites have a
much higher response rate. In these select patients,
high-dose  IL-2 may be considered for first-line therapy.
The lack of large randomized trials comparing IL-2
to DTIC or other chemotherapy means that recommenda-
tions for this guideline are based largely on phase II data
and limited phase III data. Further randomized data will
not soon become available, because no randomized tri-
als are currently ongoing or planned. Interleukin-2 is
currently widely used in the United States, and it is an
approved therapy in both Canada and the United States.
8. PRACTICE GUIDELINE DATE
This clinical practice guideline report is based on
work completed in May 2006. All approved PEBC
clinical practice guideline reports are updated regu-
larly. Please see the PEBC Web site, www.cancercare.
on.ca/index_AboutthePEBC.htm, for a complete list
of current and ongoing projects.PETRELLA et al.
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